


# How are medicines evaluated at the EMA

Presented by: Nathalie Bere Patient interaction / Stakeholders and communication Division



# **Overview of medicines development**







# **The European System**



Mutual Recognition/ Decentralised Procedure

# National Procedures

Optimised utilisation of resources Harmonised scientific opinions Harmonised information to healthcare professionals & patients





# EMA: focal point of the centralised procedure



Marketing Authorisation application Evaluation Authorisation in all EU Invented name Product information (Summary of Product Characteristics (SmPC), Labelling, Package Leaflet (PL))





# Which medicines are **mandatory** for evaluation at the EMA?

- Rare diseases
- HIV, cancer, neurodegenerative disorders, diabetes
- Auto-immune diseases, viral diseases
- All biotech products
- Gene therapy
- Monoclonal antibodies
- + Other innovative products

The EMA is **not** responsible for pricing or reimbursement



# **Eligibility "Optional Scope"**



Medicines outside the mandatory scope can also be evaluated at EMA if they meet certain criteria.



# The various roles of the EMA


The Agency is responsible for:



- The evaluation of marketing authorisation for human and veterinary applications submitted by pharmaceutical companies
- The coordination of European **pharmacovigilance** (supervision of the medicines on the market)
- The provision of **scientific advice** on the development of medicines
- The evaluation of applications for **orphan** designation in EU
- The evaluation of **paediatric investigation** plans (or waivers)
- The evaluation of **arbitration** and **referral** procedures
- The provision of good quality and independent **information** on the medicines it evaluates to patients and healthcare professionals
- The coordination of Member States' inspections



# **Medicines Lifecycle: Development and Regulatory**





# **Type of Approvals**



#### **Conditional Approval:**


**Normal:** Comprehensive data

#### **Exceptional Circumstances:**

- Comprehensive data not available and cannot be provided
- Must meet criteria (rarity, medical ethics, state of scientific knowledge)
- Comprehensive data not available; to be provided after approval
- Must fulfil scope (orphan drugs, emergency threats, serious and life-threatening diseases)
  Approval valid for 1 year, renewable



### **EMA-EU** Network








**、** 




### **Working Parties and other Groups**






# **EVALUATION OVERVIEW**





# **POST-AUTHORISATION OVERVIEW**

**EMA - CHMP - PRAC** 






### **Pharmacovigilance and Risk Management**





# **Pharmacovigilance Risk Assessment Committee (PRAC)**


Assesses aspects of risk management (detection, assessment, minimisation and communication of risk of adverse reactions)




- 1 member (+ 1 alternate) per Member State
  - plus Norway & Iceland
  - 6 experts nominated by EC
  - 1 member (+ 1 alternate) healthcare professionals
  - 1 member (+ 1 alternate) patients organisations



# Pharmacovigilance and Risk Management; Data Collection and Management









### Acronyms

- ADR = Adverse Reaction
- AR = Assessment Report
- CHMP = Committee for Medicinal Products for Human Use
- CD = Commission Decision
- D1, etc = Day 1 (procedural timeline)
- GCP Good Clinical Practice
- GLP = Good Laboratory Practice
- GMP = Good Manufacturing Practice
- LoQ = List of Questions
- LoOIs = List of Outstanding Issues

- MAH = Marketing Authorisation Holder
- MS = Member State
- OE = Oral explanation
- PASS = Post Authorisation Safety Study
- PI = product information
- PRAC = Pharmacovigilance Risk Assessment Committee
- PSUR = Periodic Safety Update Report
- RMP = Risk Management Plan
- SAG = Scientific Advisory Group
- SmPC = Summary of Product Characteristics